Teaser: Modernisation of theoretical and practical chemistry taught in academia is required for (i) expanding the chemical toolbox and (ii) educating the next generation of drug-hunters.
Drug discovery is a complex, time-consuming and a very costly process. In recent years the pharmaceutical industry has been facing increases in the cost of pharmaceutical R&D, driven by the high failure rate of projects and development candidates. Between 2005 and 2010 nine of the largest pharmaceutical companies in the world achieved an average output less than 1 new molecular entity (NME) per company per year despite their combined research expenditure climbing to $60 billion dollars during this period [1] . Failure in phase 2 clinical trials has been highlighted as a key industry challenge, as only 25% of compounds that currently enter phase 2 successfully progress to full phase 3 clinical studies. It is well-known that a large number of drug candidates fail during the development process due to problems with absorption, distribution, metabolism, excretion or toxicity (ADMET) [2] .
For this reason, the evaluation of compounds for their ADMET profile is being carried out at increasingly early stages of the development process. At the same time, strategies have been developed to remove compound structures with undesirable properties when choosing compound sets [3], in order to limit the use of a significant amount of resources to develop candidates which are ultimately unsuccessful [4] .
Medicinal chemists play a key role in the drug discovery process [5] , however the many unmet medical demands in the healthcare sector emphasise the need to evolve the medicinal chemistry discipline. To rise to the challenges in the 21 st Century [6], there is a necessity to refine the chemical toolbox for both educational and practical reasons.
Education and training of undergraduate students is, at large, still rooted in the data it will require iterative and synergistic interactions between scientists working at the chemistry/biology interface and the broader research community for years to come. Decoding the information stored in the functional genome, including thousands of predicted gene products, will only be possible with new scientific tools and methods that are fit for purpose [6, 7] . Nonetheless, due to the increasingly poor productivity of the pharmaceutical industry as measured by the number of FDAapproved NCEs, there is a need to constantly re-evaluate the drug discovery models we employ.
The purpose of this paper is to contribute to the ongoing discussion about modernisation of medicinal chemistry [5, [8] [9] [10] [11] [12] [13] [14] [15] . As discussed in the following sections, modern approaches including computational chemistry, bioisosterism, scaffold hopping and diversity-oriented synthesis to search for valuable hit compounds in new chemical space are important tools for the medicinal chemists of the future, which can be incorporated into undergraduate and postgraduate teaching with relative ease.
Computer aided hit identification
In the early stages of a drug discovery project computational assistance can be particularly useful in the identification of hits which can form the basis of a medicinal chemistry program. Any target that has structural data available, or even just known ligands, can be assessed computationally to identify potential hit compounds either using de novo design in which novel molecules are designed from scratch or by using virtual screening of databases (VS) [16, 17] . Design approaches that seek to identify hits based on their ability to complement features of a protein structure are called structure-based and approaches that look for hits based on similarity to known inhibitors or pharmacophore models are called ligand-based (for a simplistic overview, see Figure 1 ) [18] .
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Virtual screening Back in the nineties, virtual screening (VS), which is a means of efficiently docking sets of molecular structures to a target protein, emerged as a valuable tool able to guide and focus experimental efforts on smaller, filtered sets of compounds with increased probability of showing the desired biological activity. Chemical space is a term widely used in drug discovery to refer to the vast number of theoretically possible molecules. Sets of molecules can be mapped to illustrate the distribution of their properties [19] . VS allows the interrogation of large portions of chemical space without the need to physically possess the molecules in question. In the last 3 years, [24] . SGK1 has been linked to several diseases including cancer, diabetes and neurological degeneration, so selective and potent inhibitors could have a wide range of applications. A library of 2 million commercially available structures was screened to find structures similar to known inhibitors of the protein and 78 compounds were selected for biological evaluation of which 7 were active including compound 1, Figure 2 . Library synthesis was then employed to explore SAR around the two most promising hits and a series of highly potent and selective compounds with attractive physicochemical, ADME and pharmacokinetic (PK) properties was developed.
Recently, Li et. al. have reported the use of structure-based VS to identify inhibitors which target the human androgen receptor, which is known to regulate the progression of prostate cancer. They identified a binding site in the DNA binding region of the receptor which had no previously known ligands, but was identified by the group as a promising target for inhibition. By performing VS using Glide [25] they were able to identify some compounds with activities in the low micro molar range, and further shape similarity searching within the ZINC database identified even more active compounds which were used as the starting points for a full medicinal chemistry campaign resulting in compound 2 ( Figure 2 ) which exhibited submicromolar activity against the enzyme [26] .
De novo design
De novo design can be used to generate entirely novel starting points for synthesis and has the potential to design compounds with very high ligand efficiency. De novo design is attractive because it provides the opportunity to sample a much wider area of chemical space than that offered by the contents of a commercial compound library. However this approach does require a greater investment of chemical resource early in a drug discovery project, as hits generated by the software must be synthesised to establish their activity rather than simply being purchased.
Recently Yule et al. reported a series of potent, antibiotic inhibitors of the ATP binding site of DNA gyrase [27] . The fragment connection approach used within SPROUT [28] produced an initial hit molecule, which was synthesised and shown to be active against the enzyme. This hit was then developed into a series of promising inhibitors including compound 3 ( Figure 2 ) that are now being further explored for drug-like potential.
A different approach to structure-based de novo design has recently been used by the Baell group at the University of Melbourne in the design of a series of peptidomimetic inhibitors of BCL-XL using the program SYBYL [29] . BCL-XL is part of the BCL-2 family of proteins which are involved in the apoptotic cascade and thus implicated in tumorigenesis. An unsubstituted benzoyl urea scaffold was identified and then decorated with groups, which were oriented in such a way as to make desired interactions in the enzyme active sites. A thorough SAR investigation produced several inhibitors with low micromolar IC50s including compound 4 ( Figure   2 ). Ligand-based de novo design was recently employed by Rodrigues et. al. to generate promising anti-angiogenesis compounds, which inhibit the kinase VGFR-2 [30] . They used the program DOGS (design of genuine structures) to identify analogues of a known VGFR-2 inhibitor and synthetic routes to the designed compounds, including compound 5 ( Figure 2 ), which proved to be effective inhibitors of cell proliferation.
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Bioisosterism: new ways to access diverse chemical space.
When compound libraries for use in VS and HTS were first being constructed, the focus was mostly on synthesising as many compounds as possible. However, it was soon realised that chemical diversity was a more important aim and recently quality has become the guiding principle [5] . The meaning of 'quality' in this case involves a balance of multiple criteria including structural diversity, bioavailability, permeability, drug-likeness and target focus, among others [31] . In 1997, Lipinski's "Rule of Five" began a trend of focussing drug discovery efforts on confined areas of chemical space likely to contain compounds with pharmaceutically relevant properties. Since then, many related modified or related rules have been proposed [32] .
In order to enhance molecular complexity organic synthesis was called upon to support VS and HTS to accomplish the role which natural chemodiversity has played traditionally [33] in covering large and novel areas of chemical space. In particular, assistance has come from a traditional, powerful tool used by the medicinal chemist: bioisosteric replacement [34] . This approach is often used not only to improve ADME and physicochemical properties (water solubility, logP, pKa, etc.), but also to increase potency, enhance selectivity and decrease toxicity, or to gain a novel intellectual property (IP) position.
The concept of bioisosterism is based on the notion that single atoms, groups or whole molecules that exhibit similar volume, shape, and/or physicochemical properties can produce broadly similar biological effects. Two functional groups should be called isosteres if they share similar physicochemical properties. When isosteres are able to share also the same biological profile they are called bioisosteres. Bioisosteres cannot behave in exactly the same manner as the functional group they are intended to replace and, as a consequence, some bioisosteres might be successful at some targets but not at others. It could be said that while chemistry defines the isosteric similarity between groups, only the biological target can determine the similarity of bioisosteres.
Traditionally, this powerful strategy has been applied to single functional groups.
Employed since the 70´s by Wermut [35] , the proof of the importance of this technology in the modern drug discovery setting is substantiated by the fact that a comprehensive review published by Meanwell in the Journal of Medicinal Chemistry (JMC) in 2011 [36] became the most downloaded JMC article in following years.
Quite recently, the replacement of carboxylic acids with suitable bioisosteric surrogates has been reviewed [37] . The carboxylic acid has been much investigated in terms of bioisosteric replacements; this interest can be explained from its frequent presence in pharmacophores resulting in the large number (>450) of carboxylic acidcontaining drugs marketed worldwide. Bioisosteres of the -amino acidic moiety have also been reviewed recently [38] . In this case, bioisosterism of the wholeamino acid moiety is accomplished with heterocyclic bioisosteres that often display an acidic function.
A new strategy referred to as scaffold hopping has matured as a subset of bioisosteric replacement, for discovering structurally novel compounds to explore chemical space [39] . This process, also known as lead hopping, typically starts with known active compounds and modifies the central core structure of the molecule to give a novel chemotype [40] . The core may be of direct functional importance in interacting with the protein target or it may provide the necessary scaffolding to allow substitution with functional groups in the appropriate geometric configuration to interact with the target. In other words, scaffold hopping is a useful strategy in drug design to 'jump' into different areas of chemical space, for example to identify easily synthesisable small molecules that mimic complex natural products. Thus, scaffold hopping represents an attractive strategy to address novelty within confined chemical space, and by consequence achieve favourable intellectual property positions [41] . A classification of scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics, and topologybased hopping, has been recently proposed [40] . Some examples of recently Human dihydroorotate dehydrogenase (hDHODH) is a class-2 dihydroorotate dehydrogenase extensively used by proliferating cells. Its inhibition in autoimmune and inflammatory diseases, cancers, and multiple sclerosis is therefore of substantial clinical importance. The strategies employed in the development of DHODH inhibitors have been recently reviewed [43] . Scaffold hopping approaches have recently been applied to generate new lead candidates from known DHODH inhibitors. In the first example [44] a computational method able to design novel hDHODH inhibitors was developed. After a validation step, 13 novel hDHODH inhibitors were designed using a scaffold hopping strategy (e.g. compound 7, Figure   2 ). In the second example [45] , structural analogies present in two well-known DHODH inhibitors (Leflunomide and Brequinar) were identified and resulted in the design of a new class of inhibitors based on the 4-hydroxy-1,2,5-oxadiazol-3-yl scaffold (e.g. compound 8, Figure 2 ). In Figure 3 , the binding mode of compound 8 is compared with the lead compound Brequinar.
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Fragment-based drug design
Fragment-based drug design (FBDD) has over the past decade become routinely used to identify lead molecules which bind to troublesome biochemical targets for which standard techniques, such as high-throughput screening (HTS), had failed. [46] . FBDD begins with identification of small chemical fragments which bind weakly to a target, these fragments are then extended or connected to give potent lead molecules. The main benefit of this approach is its ability to explore chemical space very efficiently, with even modestly sized fragment libraries comprising molecules with less than 12 heavy atoms [47] . The successful application of FBDD has depended on a number of recent advances including better biochemical and biophysical detection techniques which are sensitive enough to identify the weak interactions seen in fragment binding, and higher throughput X-ray crystallography [48] . Indeed a critical stage in many FBDD projects is the detection of bound fragments in an appropriate ligand-binding site in crystal structures. Different from the traditional X-ray crystallography which is initially focused on acquiring the ligandprotein complex, the primary screening in FDBB employs a cocktail of ligands for each soaking experiment in order to minimise the experimental effort of screening an entire library. Effective use of FBDD also takes into account both detection method and fragment chemodiversity [49] while fragment solubility is a key design criterion.
For recent examples of successful FBDD applications, see e.g. a recent review focussed on HIV [50] .
Diversity-oriented synthesis
The strength of combinatorial chemistry (combichem) is based on the creation of large populations of molecules, or libraries that can be screened efficiently en masse Multicomponent reaction (MCR) chemistry has noted as a useful method for generating staring points for DOS with a high degree of molecular diversity.
Interestingly, as with other chemical disciplines mentioned in this review, MCR strategies often utilise routine chemical transformations comprising three or more reactants to form a product that contains all the starting components. Although MCR has existed for more than a century, the recent excitement in this field has roots in discoveries related to generation of new reactions, asymmetric catalysts and natural products and other targets of biological interest [52] . Important in the context of this review is that MCR, either as a part of DOS strategies or as an independent tool, can provide great opportunities for drug hunters and researchers interested in small molecules with biological activity [53] . This includes the development of highly specific tools for chemical genetics, but also to provide a new chemical pool for drug discovery [54] [55] [56] [57] [58] . Chemical genetics is increasingly providing scientists with a new set of complementary chemical tools to investigate biological systems [59] . Given the emerging limitations of using siRNA to completely suppress target expression as well as off-target effects, there have been calls for highly specific small molecules to be employed as chemical tools to interrogate new biological targets [60] . The constant evolution of chemical techniques and their application to biological systems will inevitably speed up the process of discovering NCEs with improved therapeutic efficacy.
Computational prediction of ADMET
Computational tools for the prediction of ADMET are becoming increasingly useful and accurate, and are now used extensively by medicinal and computational chemists [61] . However, currently available models are still some way away from being able to perfectly predict the complex and interconnected ADMET properties of a novel chemical entity. Compounds often fail in late development due to unforeseen problems with metabolism and toxicity (less so absorption, distribution and excretion as good methods for determining these properties are already well established). The earlier these problems are detected, the less money will be spent developing ultimately unsuccessful compounds and the greater the chance of designing a modified version which avoids the liabilities of its parent compound. The pharmaceutical industry is therefore keen to implement newer and better methods, both in vitro and in silico, for predicting ADMET liabilities in compounds before significant resources are invested in them. [62] . A variety of approaches have been used to generate models for the prediction of ADMET. Three of these approaches: quantitative SAR (QSAR), human knowledge based and structure-based models are described below.
QSAR models were first developed in the 1960s as a way to correlate chemical descriptors with the experimental characteristics of a compound, so as to make predictions about the properties of new molecules. QSAR models have been developed for many applications including prediction of drug binding to biological targets as well as prediction of the various aspects of ADMET. However, these models are limited by the training sets used to generate them and so the accuracy of the predictions they give depends upon the similarity of the molecules being investigated to the molecules used in the training set. There is also a tendency for more complex models of this type to be "black box" models in that the reasoning behind a given prediction is hard to interpret [61] .
Human-knowledge based models make predictions based on a thorough understanding of metabolic processes and mechanisms of toxicity. These tools have an advantage over QSAR in that they provide a rationale for their predictions which can be acted on by researchers. However, they are limited by the availability of empirical knowledge about the metabolism and toxicity of given chemical structures [62] . Available software packages include Lhasa's Derek Nexus [63, 64] and EPA's
More recently, docking based protocols have been investigated for the prediction of metabolism and toxicity by docking the drug molecules in question into crystal structures of the active sites of metabolism and toxicity related targets [66] . These targets include enzymes from the cytochrome P450 (CYP) family which are involved in phase 1 metabolism; nuclear receptors, such as the androgen receptor, which are involved in important signalling processes; and ion channels including the human ether-a-go-go (hERG) channel which is linked to irregularities in heart rhythm.
However, predictions of this kind are made more challenging by the tendency for proteins key to ADMET to be highly promiscuous with flexible or even multiple binding sites [67] .
There is a great need for more accurate and generally applicable computational tools for both medicinal chemistry, and the wider fields of toxicology and environmental protection and the rapid rate of progress in the field seems determined to meet those needs [67] .
Merging innovation and teaching
So how do we make ends meet? The speed with which we have generated new knowledge, especially at the molecular biology level, in the last part of the 20 th Century and in the beginning of the 21 st Century has been breath-taking and yet the methodologies we employ in medicinal chemistry remain, in comparison, somewhat pedestrian. Despite over half a century of medicinal chemistry practice that has matured a step at a time into a reliable discipline, there is no doubt that medicinal chemists need to take to their heart innovations in VS, DOS, chem-and bioinformatics, chemical genetics and chemical biology. This is especially the case in light of estimates that indicate that known chemical space, including public databases and corporate collections contains on the order of 100 million molecules and there may be as many as 10 60 compounds which would comply with Lipinski's rule of 5 [68] . A more modest estimate of 10 20 −10 24 molecules can be reached if a combination of known fragments are considered [69] , but this number is still staggeringly large and in fact it has been suggested that almost all small molecules (>99.9%) have never been synthesised and are still available to be prepared and tested [19] . However, just as much as astronomical "space" is a void, much of chemical space contains nothing of biological interest [70] . Therefore, the drughunter needs to be innovative in order to overcome current challenges and boundaries to deliver smarter small molecules that can modernise our healthcare.
However, the success in reducing attrition rates and sustaining productivity in an increasingly challenging environment with limited funding in both academia and industry is a challenge of immense magnitude [7] . Accordingly, medicinal chemists and other drug-hunters must have a willingness to constantly refine their knowledge and skill-sets as well as being willing to explore new strategies and paradigms.
Ironically, modernising medicinal chemistry in some ways takes us back to the early stages of the last century, when the great Paul Erlich and colleagues were stepping into new territory, by carrying out pharmacological studies using dyes from the textile industry. Clearly we understand much better where we are heading and we have a lot more experience under our belt, yet we are nowhere near finding a cure for some of the major diseases such as cancer. We are pretty good at using new tools and embracing technologies that allow us to visualise molecular interactions, draw upon previous information and knowledge to predict properties, avoid inefficiencies and redundancies and also explore new ways in which the experience and expertise can be used to explore scientific boundaries. Paradoxically, however, to meet the healthcare challenges of the 21 st Century we may have to, once again, learn how to "work in the dark" to search new areas of chemical space in the hunt for novel drugs.
To achieve this, academia and industry must work together and share technical advances, but also share the burden of developing the next generations of drug- others. This means that the students are exposed to modern approaches to drug discovery using a variety of in silico approaches including virtual screening of therapeutic targets and drug safety parameters. In addition to in silico-based approaches, the students also receive training in chemical biology, a more recent scientific discipline, based on the fundamental principles of mature disciplines such as chemistry, biochemistry, biophysics, pharmacology, medicine, bioinformatics and biostatistics. The master's students are also exposed to experts from industry including Cambridge MedChem Consulting, Sanofi-Aventis and Schrödinger, which gives the students a sense of which tools are employed in the drug discovery process.
As a part of the students gaining practical experience, the students have an obligation to conduct an internship of minimum 5 months in a research center in academia or in industry. While on placements, the students are able to sharpen their chemistry, drug delivery and clinical pharmacology while master's students can also be exposed to innovation in tissue engineering and stem cell biology. The fact that about 70% of the master's students choose to follow a PhD programme in the Netherlands or elsewhere is testament to teaching being carried out that addresses the current and future demands in drug innovation.
Although the above-mentioned institutions provide educational platforms for modern drug discovery that prepare students for meeting the current and future demands by pharmaceutical and biotech companies, it is worth pointing out that we also need to implement educational tools that help to address late-stage obstacles such as finding unanticipated toxicities in patients. Toxicities are a major problem in drug development and understanding mechanisms of toxicity could yield ways to circumvent them and/or enable exclusion of patients who might be prone to the most severe ones [73] . Off-target toxicities may be caused by the class of agent, immune reactions or toxic metabolites while individual genetic predisposition may impact treatment outcome in a number of ways [73, 74] .
Although there are incremental improvements in bringing undergraduate and postgraduate degrees in drug discovery up to speed with the demands of the health care sector, true progress in developing efficient innovative medicines is halted by the reduction in funding streams, key patent expirations, fierce price competition from generics and high regulatory hurdles. As discussed by Gharbia and Childers in two recent accounts [75, 76] , new business models are being developed which will help to guide companies through economic uncertainty.
Concluding remarks
A recent study [77] argued that medicinal chemists ought to pursue innovative goals and balance efficiency and innovation. The entrepreneurial medicinal chemist ought to broaden the discipline to chemical biology while maintaining close feedback from clinical development. The training in innovative thinking and entrepreneurship should be implemented already at the undergraduate level so one of the challenges is to make sure that science we teach at undergraduate and postgraduate level is updated and not outdated. Exploring new regions of chemical space has reinvigorated the hunt for highly specific chemical tools and innovative drugs, expanding many more potential avenues that can be pursued in order to find success. We have, in this article, focussed on computational methods, bioisosterism/scaffold hopping and DOS as these are methodologies often used to develop NCEs while at the same time topics that can easily be implemented in medicinal chemistry and chemical biology courses without a great need for financial support. We appreciate that our contribution of moving drug discovery into the 21 st Century is at large based on existing techniques and strategies that is already employed in Pharma and the more established academic institutions with a financial platform that enables state-of-the-art infrastructure. Nonetheless, we believe that better education of the drug hunter on a global scale will enable a gradual evolution of student teaching and ultimately lead to greater exposure of drug hunters to modern technologies and strategies.
In whatever shape or form the drug-hunter comes in, we live in a time where exploration and generation of new knowledge is occurring on a colossal scale; medicinal chemists can draw on an impressive volume of distilled knowledge in order to power through chemical space, but the journey will only be successful if we understand how to make the best use of both traditional and innovative tools. We are at the beginning of an exciting journey into unknown chemical space hoping to find new inhibitors and druggable targets, which will put us on the path towards cures for the major diseases we have not been able to treat so far. Halland 
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Inhibitors designed using the chemical tools described in this paper. contacts and, by reflex, with higher ligand efficiency (LE) [45] .
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